PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 5/22 — A1

(11) International Publication Number: **WO 98/33891**

(43) International Publication Date: 6 August 1998 (06.08.98)

(21) International Application Number: PCT/CA98/00049

(22) International Filing Date: 30 January 1998 (30.01.98)

(30) Priority Data:
60/037,245 31 January 1997 (31.01.97) US

(71) Applicant: HEMOSOL INC. [CA/CA]; 115 Skyway Avenue, Etobicoke, Ontario M9W 4Z4 (CA).

(72) Inventors: BELL, David, N.; 1089 Goodson Crescent, Oakville, Ontario L6H 4A7 (CA). WONG, Truman; 21 Kensington Avenue, North York, Ontario M2M 1R5 (CA).

(74) Agents: HIRONS, Robert, G. et al.; Ridout & Maybee, 18th floor, 150 Metcalfe Street, Ottawa, Ontario K2P 1P1 (CA).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: METHOD FOR THE PRODUCTION OF SELECTED LYMPHOCYTES

(57) Abstract

The invention is directed to methods for the production of selected populations of lymphocytes. Lymphocytes produced can be isolated and purified using well known and established procedures to provide a consistent lymphocyte source which one of ordinary skill in the art can modify to provide an appropriate type or an optimal level of a desired lymphocyte. The availability of such cell populations allows not only for the complete reconstitution of the depleted, defective or missing lymphocyte population in a patient, but also provides the flexibility of having sufficient cells to permit multiple or cyclic treatments. These methods for expanding target cell populations are broadly applicable to the selective expansion of several types of lymphocytes and are demonstrated to maintain phenotype as well as antigen specificity.